Cinemark
CNK
$34.78
-2.33%
Cinemark Holdings, Inc. is a leading motion picture exhibition company operating theaters primarily in the United States and internationally, generating revenue from box office receipts, concession sales, and ancillary streams like screen advertising and rentals. As one of the largest theater chains globally, Cinemark holds a strong competitive position, distinguished by its focus on premium formats and operational efficiency. The current investor narrative centers on the company's recovery from pandemic-era disruptions, with a robust box office rebound driving revenue growth, while management's $300 million buyback program and recent institutional investment signal confidence in the stock's undervaluation. However, the industry faces structural challenges from streaming competition and shifting consumer habits, making Cinemark's ability to sustain attendance and margins a key debate.…
CNK
Cinemark
$34.78
Related headlines
Investment Opinion: Should I buy CNK Today?
Rating & Thesis: We rate Cinemark as a Buy, driven by the strong box office recovery, improving profitability, and a bullish analyst consensus with an average target price of $39.27, implying +9.1% upside. The company's strategic buyback program and positive earnings trajectory support the thesis that the stock is undervalued relative to its growth potential.
Sign up to view all
CNK 12-Month Price Forecast
The AI assessment is bullish on Cinemark, driven by the strong box office recovery, improving profitability, and a favorable analyst outlook. The forward PE suggests the market expects significant earnings growth, which is plausible given the revenue trajectory. However, the high debt levels and structural industry challenges warrant a medium confidence. The stance would be upgraded if the company demonstrates sustained margin expansion and debt reduction, while a downgrade would occur if box office trends weaken or if the stock's valuation becomes stretched relative to growth.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Cinemark's 12-month outlook, with a consensus price target around $39.27 and implied upside of +12.9% versus the current price.
Average Target
$39.27
0 analysts
Implied Upside
+12.9%
vs. current price
Analyst Count
—
covering this stock
Price Range
$33 - $43
Analyst target range
Cinemark is covered by 11 analysts, with a consensus recommendation of 'buy' (mean score 2.0, where 1 is strong buy and 5 is sell). The average target price is $39.27, implying an upside of +9.1% from the current price of $35.99. The target range spans from $33.00 (low) to $43.00 (high), with the low target suggesting a potential downside of -8.3%, while the high target implies +19.5% upside. The relatively wide spread of $10 indicates moderate uncertainty, but the bullish consensus and high target suggest analysts see continued growth potential, likely driven by box office momentum and margin expansion.
Bulls vs Bears: CNK Investment Factors
Cinemark presents a compelling recovery story with strong box office momentum, improving profitability, and a bullish analyst consensus. The stock has outperformed the market significantly, and the buyback program signals management confidence. However, the company carries high debt, a low current ratio, and faces structural industry headwinds from streaming competition. The bull case currently has stronger evidence, driven by the robust recovery and positive analyst sentiment, but the high leverage and near-term valuation concerns temper enthusiasm. The most important tension is whether the box office recovery is sustainable enough to justify the current valuation and support continued earnings growth, or if structural shifts will eventually erode attendance and margins.
Bullish
- Strong Box Office Recovery: Revenue is estimated at $4.29 billion annualized, reflecting a robust rebound in box office attendance and concession sales. This recovery is driving the company's return to profitability, with net income positive and EPS of $0.05 (likely quarterly).
- Improving Profitability: Gross margin stands at 18.55% and operating margin at 10.97%, indicating that fixed costs are being spread over higher revenue. Net margin of 4.44% shows the company is profitable, though still below pre-pandemic levels.
- Analyst Consensus Buy: With 11 analysts, the consensus recommendation is 'buy' (mean score 2.0), and the average target price is $39.27, implying a +9.1% upside from the current price of $35.99. The high target of $43.00 suggests +19.5% upside.
- Strong Stock Momentum: The stock is up 41.19% over the past year and 52.95% YTD, significantly outperforming the S&P 500's +18.56% over the same period. This reflects strong investor confidence and positive market sentiment.
Bearish
- High Debt Levels: Debt-to-equity ratio is extremely high at 9.34, indicating significant leverage. This increases financial risk, especially if revenue growth stalls or interest rates rise, potentially straining cash flows.
- Low Current Ratio: The current ratio is 0.71, suggesting potential liquidity concerns, as current liabilities exceed current assets. This could limit financial flexibility in the near term.
- Valuation Near Highs: The stock trades at 92.4% of its 52-week range, near the high of $38.98. This suggests limited upside in the short term and potential for a pullback if momentum fades.
- Structural Industry Challenges: The rise of streaming services and shifting consumer habits pose long-term threats to theater attendance. This could pressure revenue growth and margins over time, despite the current recovery.
CNK Technical Analysis
Cinemark's stock is in a strong uptrend, with a 1-year price change of +41.19% and a YTD gain of +52.95%, significantly outperforming the S&P 500's +18.56% over the same period. The current price of $35.99 sits at 92.4% of its 52-week range (low $21.60, high $38.98), indicating the stock is trading near its highs, reflecting robust momentum and investor optimism, though it also suggests potential overextension in the short term.
Beta
0.99
0.99x market volatility
Max Drawdown
-27.9%
Largest decline past year
52-Week Range
$22-$39
Price range past year
Annual Return
+34.8%
Cumulative gain past year
| Period | CNK Return | S&P 500 |
|---|---|---|
| 1m | -4.9% | +2.0% |
| 3m | +16.9% | +1.0% |
| 6m | +23.1% | +11.8% |
| 1y | +34.8% | +18.1% |
| ytd | +47.8% | +11.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CNK Fundamental Analysis
Cinemark's revenue trajectory is recovering strongly, with the latest quarterly revenue estimated at $4.29 billion (annualized), reflecting a rebound in box office attendance and concession sales. The company's gross margin stands at 18.55%, while operating margin is 10.97%, indicating improving profitability as fixed costs are spread over higher revenue. Net income is positive, with EPS of $0.05 (likely quarterly), and the net margin of 4.44% shows the company is profitable, though margins remain below pre-pandemic levels due to higher operating costs.
Quarterly Revenue
N/A
N/A
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
N/A
Latest Quarter
Free Cash Flow
N/A
Last 12 Months
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CNK Overvalued?
Given Cinemark's positive net income, the PE ratio is the primary valuation metric. The trailing PE is 19.69x, while the forward PE is 13.75x, implying the market expects significant earnings growth, with the forward PE suggesting a 30% earnings increase. This gap indicates optimism about future profitability, driven by box office recovery and cost discipline.
PE
19.7x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
11.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Cinemark's balance sheet is highly leveraged, with a debt-to-equity ratio of 9.34, which amplifies financial risk. The current ratio of 0.71 indicates potential liquidity issues, as current liabilities exceed current assets, which could constrain operational flexibility. While the company is profitable with a net margin of 4.44%, margins remain thin and could be vulnerable to cost inflation or a slowdown in box office revenue. The reliance on a strong box office slate for revenue concentration in the exhibition business is a key operational risk, as any disruption in film production or distribution could directly impact attendance and earnings.
FAQ
The key risks are financial, competitive, and macro-related. Financially, the high debt-to-equity ratio of 9.34 and low current ratio of 0.71 pose liquidity and solvency risks. Competitively, streaming services continue to challenge theater attendance, which could erode revenue over time. Macro risks include economic downturns that reduce discretionary spending on entertainment. Additionally, the stock's beta of 0.986 means it moves with the market, so a broad market selloff could impact CNK. The most severe risk is a prolonged box office slump, which could lead to a -40% decline to the 52-week low of $21.60.
The 12-month forecast for CNK is moderately bullish. In the base case (50% probability), the stock is expected to trade in the $37-$40 range, aligning with the analyst average target of $39.27. In the bull case (30% probability), it could reach $40-$43, driven by a stronger-than-expected box office. In the bear case (20% probability), it could fall to $30-$33 if the recovery stalls. The most likely scenario is the base case, assuming continued box office growth and stable margins. Investors should monitor quarterly earnings and box office trends to gauge which scenario is unfolding.
CNK appears fairly valued to slightly undervalued based on forward metrics. The trailing PE of 19.69x is above the market average, but the forward PE of 13.75x indicates the market expects significant earnings growth, which is supported by analyst EPS estimates of $3.34. The PS ratio of 0.86x is low, suggesting the market is not paying a premium for revenue. Compared to its own history, the stock is trading near its 52-week high, but the forward valuation is reasonable. The market is pricing in a successful box office recovery and margin expansion, which seems justified given the current trends.
CNK is a good buy for investors with a moderate risk appetite, given the strong box office recovery and analyst consensus 'buy' rating. The average target price of $39.27 implies a +9.1% upside, and the forward PE of 13.75x suggests reasonable valuation relative to expected growth. However, the high debt-to-equity ratio of 9.34 and low current ratio of 0.71 introduce financial risk. The stock is suitable for those who believe in the sustainability of the theatrical recovery and are comfortable with potential volatility. It may not be ideal for risk-averse investors or those seeking immediate income, as the dividend yield is only 1.45%.
CNK is more suitable for long-term investment, given its cyclical nature and recovery phase. The stock has shown strong momentum, but the high beta (0.986) and volatility make it less ideal for short-term trading. The company's earnings visibility is improving, but structural industry challenges suggest a longer horizon to realize full value. A minimum holding period of 12-24 months is recommended to allow the box office recovery to fully materialize and for the company to reduce debt. Short-term traders may find opportunities in the stock's volatility, but the risk is elevated due to leverage and market sentiment.